Lexaria Bioscience Corp. announced on August 15, 2025, that its Contract Research Organization has completed the 'last patient last visit' milestone in Lexaria’s Phase 1b glucagon-like peptide-1 study in Australia, GLP-1-H24-4.
This achievement signifies the completion of patient treatment in the study, marking a critical transition to the laboratory analysis phase. Thousands of samples collected during the study are now being processed, analyzed, and recorded.
Lexaria is currently blinded to the data, which will be compiled and analyzed before being released. The completion of this milestone brings the company closer to reporting comprehensive results from this major chronic human trial, anticipated in the fourth quarter of calendar 2025.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.